Non-Platelet Thromboxane Generation is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery
Publication Title
Journal of the American College of Cardiology
Document Type
Abstract
Publication Date
3-2017
Keywords
cards
Abstract
Aim Non-platelet thromboxane generation, measured by urinary 11-dehydroTXB2 in subjects on aspirin therapy, has been shown to be independently associated with vein graft thrombosis 6 months after coronary artery bypass graft (CABG) surgery. We investigated its ability to predict, along with other patient demographic, clinical and laboratory factors, late-term outcome after CABG surgery.
Methods:We analyzed data from 293 subjects enrolled in the multicenter Reduction in Graft Occlusion Rates study who were on aspirin therapy and survived to graft patency assessment 6 months after CABG surgery. The primary endpoint was the composite of mortality, myocardial infarction (MI), stroke and repeat revascularization with mortality as a secondary endpoint. Post-operative events prior to the 6 month evaluation (194±30 days) were excluded. Proportional hazard Cox survival modeling was used to assess determinants of outcome. Predictors reaching significance (unadjusted p
Results: There were 67 primary endpoints, including 26 mortalities, during a mean follow-up period of 1566±484 days. Independent predictors of outcome on multivariate modeling are shown below.
Conclusions: Non-platelet thromboxane generation 6-months after CABG surgery is a significant independent predictor of late-term events, including mortality.
Clinical Institute
Cardiovascular (Heart)
Specialty/Research Institute
Center for Cardiovascular Analytics, Research + Data Science (CARDS)
Specialty/Research Institute
Cardiology
